New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The standout story remains Wegovy, particularly its new oral formulation
The private funding rose 38% amid growing international collaborations and CDMO demand
Funds to support product expansion, quick commerce growth, and manufacturing scale-up for holistic period care solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Pharma giant targets new standards of care
By cutting pain crises & boosting haemoglobin
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Subscribe To Our Newsletter & Stay Updated
